News | August 16, 2022
Marksans Pharma posts Q1FY23consolidated PAT at Rs. 59.71 Cr
The company has reported total income of Rs. 450.26 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 450.26 crores during the period ended June 30, 2022.
The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.
Marksans Pharma has reported consolidated financial results for the period ended December 31, 2021
The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
The Subsidiary has received one inspectional observation in Form 483
Alkem Medtech to acquire 100% stake of Bombay Ortho
USFDA inspection at Emcure Pharmaceuticals API facility
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
Subscribe To Our Newsletter & Stay Updated
